Andy Rawstron, PhD

Leeds Teaching Hospitals NHS Trust, United Kingdom

Poster(s):

• 1216 - BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.

• 1223 - Depletion of normal B-cells, defined as < 20 cells/µL by high-sensitivity analysis, identifies early-stage CLL and MBL patients at increased risk of severe infection and early mortality.

• 1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.

• 1434 - STATIC TRIAL (Stopping Therapy to Avoid Treatment-resistance In CLL): A randomised phase III trial comparing intermittent with continuous treatment strategies in CLL

• 1437 - Effect of targeted treatment on IGHV subset #2 and #8 patients in CLL: Comparison of MRD defined Ibrutinib plus Venetoclax treatment to the Ibrutinib and FCR arms of the FLAIR Trial